ICON Public Limited (NASDAQ:ICLR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of ICON Public Limited (NASDAQ:ICLR) have been given an average recommendation of “Moderate Buy” by the thirteen analysts that are currently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $290.20.

Several equities analysts have commented on the stock. Leerink Partners reiterated an “outperform” rating and issued a $255.00 price objective (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. The Goldman Sachs Group cut their price objective on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Truist Financial lowered their target price on ICON Public from $363.00 to $295.00 and set a “buy” rating on the stock in a research note on Monday, October 28th. Barclays dropped their price objective on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Finally, TD Cowen cut their target price on ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a research report on Friday, October 25th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ashton Thomas Private Wealth LLC bought a new stake in shares of ICON Public during the second quarter worth $54,000. ORG Partners LLC acquired a new position in shares of ICON Public in the second quarter valued at approximately $59,000. EverSource Wealth Advisors LLC raised its holdings in ICON Public by 39.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock valued at $129,000 after buying an additional 111 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its position in ICON Public by 119.6% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company’s stock worth $130,000 after buying an additional 226 shares during the period. Finally, First Horizon Advisors Inc. grew its holdings in ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after acquiring an additional 151 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Stock Down 1.3 %

ICLR stock opened at $208.15 on Friday. The company has a market cap of $17.17 billion, a price-to-earnings ratio of 23.21, a P/E/G ratio of 1.57 and a beta of 1.21. ICON Public has a twelve month low of $183.38 and a twelve month high of $347.72. The business has a 50 day moving average price of $233.99 and a two-hundred day moving average price of $286.74. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period in the previous year, the company posted $3.10 earnings per share. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. Analysts anticipate that ICON Public will post 13.42 EPS for the current fiscal year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.